Sign Out
Fertility: Latanoprost has not been found to have any effect on male or female fertility in animal studies (see Pharmacology: Toxicology: Preclinical Safety Data: Impairment of Fertility: Latanoprost under Actions).
Pregnancy: This medicinal product does not increase the spontaneous incidence of birth defects, but it has potential hazardous pharmacological effects with respect to the course of pregnancy, to the unborn or neonate.
Latanoprost has been shown to cause embryofetal toxicity in rabbits characterized by increase incidences of late resorption and abortion and reduced foetal weight when given in intravenous doses approximately 100 times the human dose.
Xalatan should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus (see Pharmacology: Toxicology: Preclinical Safety Data: Impairment of Fertility under Actions).
Lactation: The active substance in Xalatan and its metabolites may pass into breast milk and Xalatan should therefore be used with caution in nursing women.
